Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

Merck claims key FDA okay for Bavencio in kidney cancer

Merck claims key FDA okay for Bavencio in kidney cancer Bristol-Myers Squibb’s Opdivo (nivolumab).

Bad news for BMS as Keytruda kidney cancer combo approved

Bad news for BMS as Keytruda kidney cancer combo approved competition with Bristol-Myers Squibb’s Opdivo and Yervoy.

Avenir Global acquires UK communications firm Hanover

Avenir Global acquires UK communications firm Hanover The firm has a roster of pharmaceutical clients, including Eli Lilly, Novartis, Bristol Myers-Squibb, Roche and Takeda.

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy IFM Tre has only been in existence a few months, coalescing from assets that were left over when Bristol-Myers Squibb acquired IFM Therapeutics for $2.3bn in 2017.

BMS closes on Celgene merger after rebel investors bow out

BMS closes on Celgene merger after rebel investors bow out News on Revlimid patent also positive. Bristol-Myers Squibb chalked up a morale-boosting victory in its bid to close its $74bn merger with Celgene, after a rebel investment group abandoned ... Glass Lewis meanwhile said the proposed merger is

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics